The three most common adverse events were fatigue ( in 32.7 % of patients in the 12-week group and 46.5 % of patients in the 24-week group ) , headache ( in 27.9 % and 30.8 % , respectively ) , and nausea ( in 17.8 % and 20.3 % , respectively ) .